Monday, June 1, 2026
ADVT 
International

232 confirmed dead in Jan 1 Japan earthquake

Darpan News Desk IANS, 17 Jan, 2024 02:46 PM
  • 232 confirmed dead in Jan 1 Japan earthquake

Tokyo, Jan 17 (IANS) At least 232 people have been confirmed dead in the devastating 7.6-magnitude earthquake that struck Japan's Ishikawa prefecture on January 1, local officials said on Wednesday.

According to the prefectural government, the death toll was updated on Wednesday morning after an additional 10 casualties was reported by the city of Wajima, one of the worst-hit by the massive temblor, reports Xinhua news agency.

Local authorities said these fatalities were discovered in the vicinity of the Wajima Morning Market, a popular tourist spot that suffered extensive damage in the earthquake-triggered fires immediately following the seismic event.

Since last week, the Wajima Morning Market has been the focus of large-scale search and rescue operations.

The number of individuals unaccounted for has decreased by one, leaving Wajima city with 17 missing persons and Suzu city with four, totaling 21 people.

According to local media reports, the damage to residences has reached a staggering 22,374 confirmed cases, and there is a high likelihood that the number of affected buildings will significantly increase as further assessments are conducted.

In cities of Wajima and Suzu, the extent of the damage is still described as "numerous", with the actual situation remaining unclear, reported national news agency Kyodo.

The January 1 temblor, officially named 2024 Noto Peninsula Earthquake, is the first to kill more than 100 people in the country since the 2016 Kumamoto tremors in Japan's southwestern region, which claimed 276 lives.

MORE International ARTICLES

AstraZeneca resuming US testing of COVID-19 vaccine

AstraZeneca resuming US testing of COVID-19 vaccine
The AstraZenca vaccine, developed with Oxford University, is one of several coronavirus vaccine candidates in final-stage testing around the world.

AstraZeneca resuming US testing of COVID-19 vaccine

FDA approves first COVID-19 drug: antiviral remdesivir

FDA approves first COVID-19 drug: antiviral remdesivir
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

FDA approves first COVID-19 drug: antiviral remdesivir

Here we go again: Trump, Biden reprise debate duel

Here we go again: Trump, Biden reprise debate duel
Instead, they're bracing for another show of vintage Trump, one in which he'll seek to be heard even in spite of his muted microphone.

Here we go again: Trump, Biden reprise debate duel

Getting ready for the gong show: Trump v. Biden II

Getting ready for the gong show: Trump v. Biden II
It's the sequel to last month's debate horror show between Donald Trump and Joe Biden, an invective-laced 90 minutes that laid bare the depths to which political discourse can sink in an American election year.

Getting ready for the gong show: Trump v. Biden II

US overdose deaths appear to rise amid coronavirus pandemic

US overdose deaths appear to rise amid coronavirus pandemic
Davidson lost his job. He started staying home alone in his apartment near Georgetown, Kentucky — depressed and yearning for his recovery support group that had stopped gathering in person, said his cousin Melanie Wyatt.

US overdose deaths appear to rise amid coronavirus pandemic

Pfizer: Mid-November earliest it can seek virus vaccine OK

Pfizer: Mid-November earliest it can seek virus vaccine OK
Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.

Pfizer: Mid-November earliest it can seek virus vaccine OK